Experiments and Dynamic Treatment Regimes S.A. Murphy Univ. of Michigan Yale: November, 2005.

Slides:



Advertisements
Similar presentations
Piloting and Sizing Sequential Multiple Assignment Randomized Trials in Dynamic Treatment Regime Development 2012 Atlantic Causal Inference Conference.
Advertisements

Treatment Effect Heterogeneity & Dynamic Treatment Regime Development S.A. Murphy.
11 Confidence Intervals, Q-Learning and Dynamic Treatment Regimes S.A. Murphy Time for Causality – Bristol April, 2012 TexPoint fonts used in EMF. Read.
Using Clinical Trial Data to Construct Policies for Guiding Clinical Decision Making S. Murphy & J. Pineau American Control Conference Special Session.
1 Developing Dynamic Treatment Regimes for Chronic Disorders S.A. Murphy Univ. of Michigan RAND: August, 2005.
1 Dynamic Treatment Regimes Advances and Open Problems S.A. Murphy ICSPRAR-2008.
1 Developing Adaptive Treatment Strategies using MOST Experimental Designs S.A. Murphy Univ. of Michigan Dallas: December, 2005.
Experiments and Dynamic Treatment Regimes S.A. Murphy Univ. of Michigan JSM: August, 2005.
SMART Designs for Constructing Adaptive Treatment Strategies S.A. Murphy 15th Annual Duke Nicotine Research Conference September, 2009.
Dynamic Treatment Regimes, STAR*D & Voting D. Lizotte, E. Laber & S. Murphy LSU ---- Geaux Tigers! April 2009.
Substance Abuse, Multi-Stage Decisions, Generalization Error How are they connected?! S.A. Murphy Univ. of Michigan CMU, Nov., 2004.
An Experimental Paradigm for Developing Dynamic Treatment Regimes S.A. Murphy Univ. of Michigan March, 2004.
Constructing Dynamic Treatment Regimes & STAR*D S.A. Murphy ICSA June 2008.
Screening Experiments for Developing Dynamic Treatment Regimes S.A. Murphy At ICSPRAR January, 2008.
SMART Designs for Developing Adaptive Treatment Strategies S.A. Murphy K. Lynch, J. McKay, D. Oslin & T.Ten Have CPDD June, 2005.
Dynamic Treatment Regimes: Challenges in Data Analysis S.A. Murphy Survey Research Center January, 2009.
Q-Learning and Dynamic Treatment Regimes S.A. Murphy Univ. of Michigan IMS/Bernoulli: July, 2004.
1 A Prediction Interval for the Misclassification Rate E.B. Laber & S.A. Murphy.
Sizing a Trial for the Development of Adaptive Treatment Strategies Alena I. Oetting The Society for Clinical Trials, 29th Annual Meeting St. Louis, MO.
Screening Experiments for Dynamic Treatment Regimes S.A. Murphy At ENAR March, 2008.
Experiments and Dynamic Treatment Regimes S.A. Murphy Univ. of Michigan Florida: January, 2006.
SMART Experimental Designs for Developing Adaptive Treatment Strategies S.A. Murphy NIDA DESPR February, 2007.
Hypothesis Testing and Dynamic Treatment Regimes S.A. Murphy Schering-Plough Workshop May 2007 TexPoint fonts used in EMF. Read the TexPoint manual before.
Michigan Team February, Amy Wagaman Bibhas Chakraborty Herle McGowan Susan Murphy Lacey Gunter Danny Almirall Anne Buu.
An Experimental Paradigm for Developing Adaptive Treatment Strategies S.A. Murphy Univ. of Michigan UNC: November, 2003.
1 A Confidence Interval for the Misclassification Rate S.A. Murphy & E.B. Laber.
Experiments and Dynamic Treatment Regimes S.A. Murphy Univ. of Michigan PSU, October, 2005 In Honor of Clifford C. Clogg.
Planning Survival Analysis Studies of Dynamic Treatment Regimes Z. Li & S.A. Murphy UNC October, 2009.
Statistical Issues in Developing Adaptive Treatment Strategies for Chronic Disorders S.A. Murphy Univ. of Michigan CDC/ATSDR: March, 2005.
SMART Experimental Designs for Developing Adaptive Treatment Strategies S.A. Murphy RWJ Clinical Scholars Program, UMich April, 2007.
Hypothesis Testing and Dynamic Treatment Regimes S.A. Murphy, L. Gunter & B. Chakraborty ENAR March 2007.
1 SMART Designs for Developing Adaptive Treatment Strategies S.A. Murphy K. Lynch, J. McKay, D. Oslin & T.Ten Have UMichSpline February, 2006.
Dynamic Treatment Regimes, STAR*D & Voting D. Lizotte, E. Laber & S. Murphy ENAR March 2009.
A Finite Sample Upper Bound on the Generalization Error for Q-Learning S.A. Murphy Univ. of Michigan CALD: February, 2005.
An Experimental Paradigm for Developing Adaptive Treatment Strategies S.A. Murphy Univ. of Michigan ACSIR, July, 2003.
Dynamic Treatment Regimes, STAR*D & Voting D. Lizotte, E. Laber & S. Murphy Psychiatric Biostatistics Symposium May 2009.
An Experimental Paradigm for Developing Adaptive Treatment Strategies S.A. Murphy Univ. of Michigan February, 2004.
Methods for Estimating the Decision Rules in Dynamic Treatment Regimes S.A. Murphy Univ. of Michigan IBC/ASC: July, 2004.
Discussion of Profs. Robins’ and M  ller’s Papers S.A. Murphy ENAR 2003.
1 Possible Roles for Reinforcement Learning in Clinical Research S.A. Murphy November 14, 2007.
Experiments and Dynamic Treatment Regimes S.A. Murphy Univ. of Michigan April, 2006.
SMART Designs for Developing Dynamic Treatment Regimes S.A. Murphy MD Anderson December 2006.
SMART Experimental Designs for Developing Adaptive Treatment Strategies S.A. Murphy ISCTM, 2007.
1 A Prediction Interval for the Misclassification Rate E.B. Laber & S.A. Murphy.
Experiments and Adaptive Treatment Strategies S.A. Murphy Univ. of Michigan Chicago: May, 2005.
1 Dynamic Treatment Regimes: Interventions for Chronic Conditions (such as Poverty or Criminality?) S.A. Murphy Univ. of Michigan In Honor of Clifford.
SMART Designs for Developing Dynamic Treatment Regimes S.A. Murphy Symposium on Causal Inference Johns Hopkins, January, 2006.
Experiments and Dynamic Treatment Regimes S.A. Murphy At NIAID, BRB December, 2007.
1 Machine/Reinforcement Learning in Clinical Research S.A. Murphy May 19, 2008.
Adaptive Treatment Strategies S.A. Murphy CCNIA Proposal Meeting 2008.
Adaptive Treatment Strategies S.A. Murphy Workshop on Adaptive Treatment Strategies Convergence, 2008.
Practical Application of Adaptive Treatment Strategies in Trial Design and Analysis S.A. Murphy Center for Clinical Trials Network Classroom Series April.
Experiments and Dynamic Treatment Regimes S.A. Murphy Univ. of Michigan January, 2006.
Hypothesis Testing and Adaptive Treatment Strategies S.A. Murphy SCT May 2007.
Adaptive Treatment Design and Analysis S.A. Murphy TRC, UPenn April, 2007.
Adaptive Treatment Strategies: Challenges in Data Analysis S.A. Murphy NY State Psychiatric Institute February, 2009.
DOCTORAL SEMINAR, SPRING SEMESTER 2007 Experimental Design & Analysis Further Within Designs; Mixed Designs; Response Latencies April 3, 2007.
Sequential, Multiple Assignment, Randomized Trials and Treatment Policies S.A. Murphy UAlberta, 09/28/12 TexPoint fonts used in EMF. Read the TexPoint.
بسم الله الرحمن الرحيم * this presentation about :- “experimental design “ * Induced to :- Dr Aidah Abu Elsoud Alkaissi * Prepared by :- 1)-Hamsa karof.
Overview of Adaptive Treatment Regimes Sachiko Miyahara Dr. Abdus Wahed.
Background to Adaptive Design Nigel Stallard Professor of Medical Statistics Director of Health Sciences Research Institute Warwick Medical School
Sequential, Multiple Assignment, Randomized Trials and Treatment Policies S.A. Murphy MUCMD, 08/10/12 TexPoint fonts used in EMF. Read the TexPoint manual.
Engineering Statistics ENGR 592 Prepared by: Mariam El-Maghraby Date: 26/05/04 Design of Experiments Plackett-Burman Box-Behnken.
1 SMART Designs for Developing Adaptive Treatment Strategies S.A. Murphy K. Lynch, J. McKay, D. Oslin & T.Ten Have NDRI April, 2006.
Simulation Study for Longitudinal Data with Nonignorable Missing Data Rong Liu, PhD Candidate Dr. Ramakrishnan, Advisor Department of Biostatistics Virginia.
Motivation Using SMART research designs to improve individualized treatments Alena Scott 1, Janet Levy 3, and Susan Murphy 1,2 Institute for Social Research.
An Experimental Paradigm for Developing Adaptive Treatment Strategies S.A. Murphy NIDA Meeting on Treatment and Recovery Processes January, 2004.
Designing An Adaptive Treatment Susan A. Murphy Univ. of Michigan Joint with Linda Collins & Karen Bierman Pennsylvania State Univ.
SMART Trials for Developing Adaptive Treatment Strategies S.A. Murphy Workshop on Adaptive Treatment Designs NCDEU, 2006.
BHS Methods in Behavioral Sciences I
Presentation transcript:

Experiments and Dynamic Treatment Regimes S.A. Murphy Univ. of Michigan Yale: November, 2005

2 Joint work with –Derek Bingham (Simon Fraser) –Linda Collins (PennState) And informed by discussions with –Vijay Nair (U. Michigan) –Bibhas Chakraborty (U. Michigan) –Vic Strecher (U. Michigan)

3 Outline Dynamic Treatment Regimes Challenges in Experimentation Defining Effects and Aliasing Examples

4 Dynamic treatment regimes are individually tailored treatments, with treatment type and dosage changing with ongoing subject need. Mimic Clinical Practice. Dynamic Treatment Regimes

5 k Decisions on one individual Observation made prior to j th decision point Treatment at j th decision point Primary outcome Y is a specified summary of decisions and observations

6 A dynamic treatment regime is a vector of decision rules, one per decision where each decision rule inputs the available information and outputs a recommended treatment decision.

7 Challenges in Experimentation

8 Dynamic Treatment Regimes (review) Constructing decision rules is a multi-stage decision problem in which the system dynamics are unknown. Analysis methods for observational data dominate statistical literature (Murphy, Robins, Moodie & Richardson, Tsiatis) Better data provided by sequential multiple assignment randomized trials: randomize at each decision point— à la full factorial.

9 Reality

10 Challenges in Experimentation Dynamic Treatment Regimes are multi-component treatments: many possible components decision options for improving patients are often different from decision options for non-improving patients, multiple components employed simultaneously medications, adjunctive treatments, delivery mechanisms, behavioral contingencies, staff training, monitoring schedule……. Future: series of screening/refining, randomized trials prior to confirmatory trial --- à la Fisher/Box

11 Screening experiments (review) 1)Goal is to eliminate inactive factors (e.g. components) and inactive effects. 2)Each factor at 2 levels 3)Screen marginal causal effects 4)Design experiment using working assumptions concerning the negligibility of certain effects. (Think ANOVA) 5)Designs and analyses permit one to determine aliasing (caused by false working assumptions) 6)Minimize formal assumptions

12 Screening experiments When the goal is to construct/optimize a dynamic treatment regime can we design screening experiments using working assumptions concerning the marginal causal effects and provide an analysis method that permits the determination of the aliasing??

13 Defining the Effects

14 Defining the stage 2 effects Two decisions (two stages): Define effects involving T 2 in an ANOVA decomposition of

15 Defining the stage 1 effects (T 1 )

16 Defining the stage 1 effects

17 Defining the stage 1 effects Define Define effects involving only T 1 in an ANOVA decomposition of

18 Why marginal, why uniform? Define effects involving only T 1 in an ANOVA decomposition of 1)The defined effects are causal. 2)The defined effects are consistent with tradition in experimental design for screening. –The main effect for one treatment factor is defined by marginalizing over the remaining treatment factors using an uniform distribution.

19 Why marginal, why uniform? 2)The defined effects are marginal consistent with tradition in experimental design for screening. –The main effect for one treatment factor is defined by marginalizing over the remaining factors using an uniform distribution. When there is no R, the main effect for treatment T 1 is

20 An Aside: Ideally you’d like to replace by (X 2 is a vector of intermediate outcomes) in defining the effects of T 1.

21 Use an ANOVA-like decomposition: Representing the effects

22 where Causal effects: Nuisance parameters: and

23 General Formula New ANOVA Z 1 matrix of stage 1 treatment columns, Z 2 is the matrix of stage 2 treatment columns, Y is a vector Classical ANOVA

24 Aliasing {Z 1, Z 2 } is determined by the experimental design The defining words (associated with an fractional factorial experimental design) identify common columns in the collection {Z 1, Z 2 } ANOVA

25 Aliasing ANOVA Consider designs with a shared column in both Z 1 and Z 2 only if the column in Z 1 can be safely assumed to have a zero η coefficient or if the column in Z 2 can be safely assumed to have a zero β, α coefficient. The defining words provide the aliasing in this case.

26 Simple Examples

27 Five Factors: M 1, E, C, T, A 2 (only for R=1), M 2 (only for R=0), each with 2 levels (2 6 = 64 simple dynamic treatment regimes) The budget permits 16 cells --16 simple dynamic treatment regimes. Simple Example

28 Design: 1=M 2 M 1 ECT=A 2 M 1 ECT M 1 E C T A 2 =M

29 Assumptions A 2 C, A 2 T, M 2 E, M 2 T and CE along with the main effects in stage 1 and 2 are of primary interest. Working Assumption: All remaining causal effects are likely negligible. Formal Assumption: Consider designs for which a shared column in Z 1 and Z 2 occurs only if the column in Z 1 can be safely assumed to have a zero η coefficient (concerns interactions of stage 1 factors with R) or if the column in Z 2 can be safely assumed to have a zero β/α coefficient (stage 2 effects).

30 Design 1 No formal assumptions. 1=M 1 ECT The design column for A 2 /M 2 is crossed with stage 1 design. EC is aliased with M 1 T. The interaction EC is of primary interest and the working assumption was that M 1 T is negligible. A 2 C is aliased with A 2 M 1 ET. The interaction A 2 C is of primary interest and the working assumption was that A 2 M 1 ET is negligible.

31 Design 1 I=M 1 ECT Screening model: The estimator estimates the sum of the effects of CE and M 1 T.

32 Design 2 Formal assumption: No three way and higher order stage 2 causal effects & no four way and higher order effects involving R and stage 1 factors. 1=M 2 M 1 ECT=A 2 M 1 ECT M 2 T and A 2 T are aliased with M 1 CE; the interaction M 2 T (A 2 T) is of primary interest and the working assumption was that M 1 CE is negligible. M 2 M 1 T is negligible so CE is not aliased.

33 Design 2 Screening model: The estimator estimates the sum of the effects of M 2 T and of M 1 CE

34 Design 3 Formal assumption: No four way and higher order causal effects & no three way and higher order effects involving R and first stage factors. I=M 2 M 1 ECT=A 2 M 1 ECT CE aliased with both A 2 M 1 T and with M 2 M 1 T

35 Design 3 Screening model: The estimator estimates the sum of the effects of CE and A 2 M 1 T

36 Discussion In classical screening experiments we Screen marginal causal effects Design experiment using working assumptions concerning the negligibility of the effects. Designs and analyses permit one to determine aliasing Minimize formal assumptions We can do this as well when screening for multi-stage decision problems!

37 Discussion Compare this to using observational studies to construct dynamic treatment regimes –Uncontrolled selection bias (causal misattributions) –Uncontrolled aliasing. Secondary analyses would assess if variables collected during treatment should enter decision rules. This seminar can be found at: lsa.umich.edu/~samurphy/seminars/Yale11.05.ppt

38 Reality

39 Conceptual Model The meaning of T 2 depends on R